Navigation Links
Mindray Medical to Acquire a Controlling Stake in Hunan Changsha TDR Biotech
Date:12/20/2011

SHENZHEN, China, Dec. 20, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today an agreement to acquire a controlling stake of Hunan Changsha Tiandiren Biotech Co., Ltd. ("TDR"). The terms of the agreement were not disclosed as the transaction is non-material to Mindray's financial statements.

Founded in 1997 and based in Hunan, China, TDR is a domestic manufacturer of microbiology analysis solutions that specialize in microbial identification and antibiotic susceptibility testing (ID/AST) and the blood culture system. Clinical laboratories use the ID/AST system to identify microbes and perform antibiotic susceptibility testing, while they use the blood culture system to recover pathological organisms. The rapid reporting of ID/AST test results and a continuous-monitoring blood culture system can result in better antibiotic management. Last year, the market for ID/AST and blood culture system was estimated at approximately $139 million in China. It is expected to grow 15-20% annually. Internationally, the market was estimated at $2.25 billion in 2010 and is expected to grow 5% annually.

Through this transaction, Mindray will be able to combine its strong platforms in sales, manufacturing, R&D, quality assurance and other resources with TDR's technology and expertise in the microbiology analysis business. TDR's strength in reagents is expected to complement Mindray's strength in analyzers.

"This transaction continues to show our commitment to expand the IVD product portfolio," said Mr. Minghe Cheng, Mindray's Chief Strategic Officer. "TDR's products will be a great addition to our existing IVD product line. Microbiology analysis is an important segment within IVD. It is an emerging yet promising category in China, based on favorable domestic policies to develop the overall industry as well as the government's specific focus on preventing antibiotic overuse."

Cautionary Note Regarding Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including without limitation, the projections of the annual growth rate of the microbial diagnostic market in China and internationally, any expected benefits of this transaction to either of Mindray or TDR, expected complements of TDR's business lines to Mindray's businesses, expansion of Mindray's product portfolio in microbiology analysis and expectations regarding governmental policies or development in China of the microbiology analysis market, are forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our public filings with the Securities and Exchange Commission. For a discussion of other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 4 of our annual report on Form 20-F. Any projections in this release are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, we will not necessarily update the information. Such information speaks only as of the date of this release.

About Mindray

We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain our global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China, we supply through our worldwide distribution network a broad range of products across three primary business segments, namely patient monitoring and life support, in-vitro diagnostic, and medical imaging systems. For more information, please visit http://ir.mindray.com.

For investor and media inquiries, please contact:

In the U.S.:

   Hoki Luk
   Western Bridge, LLC
   Tel:   +1-646-808-9150
   Email: hoki.luk@westernbridgegroup.com

   In China:

   Cathy Gao
   Mindray Medical International Limited
   Tel:   +86-755-8188-8023
   Email: cathy.gao@mindray.com


'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mindray Medical to Acquire a Controlling Stake in Zhejiang Greenlander Information Technology
2. Mindray to Launch New DC-T6 Ultrasound System at RSNA
3. Mindray Announces Partnership with Epiphany Cardiography Products, LLC
4. Mindray to Hold Annual General Meeting in Hong Kong on December 19, 2011
5. Mindray Announces Up to $100 Million Share Repurchase Program
6. Mindray Announces Third Quarter 2011 Financial Results
7. Mindray Medical to Exhibit at MEDICA 2011 in Dusseldorf, Germany from November 16-19, 2011
8. Mindray Medical to Exhibit New Products at 66th China International Medical Equipment Fair
9. Mindray to Report Third Quarter 2011 Financial Results on November 7, 2011
10. Mindray Introduces Enhancements for M Series Ultrasound Platforms at ASA
11. Mindray Announces Expansion of its A Series Anesthesia Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... -- FDA 510(k) clearance covers Confocal ... urological and surgical applications Mauna Kea ... the multidisciplinary confocal laser endomicroscopy (CLE) platform, today ... with the 12 th 510(k) clearance from ... new FDA clearance covers Confocal Miniprobes indicated for ...
(Date:5/25/2016)... , May 25, 2016  According to Kalorama Information, ... billion in 2015.  Though these are challenging times ... opportunity for success for companies that remain optimistic ... of new growth prospects medical device companies spend ... and development (R&D) than do companies in other ...
(Date:5/25/2016)... PARIS , May 25, 2016 ... system disorders, announces that an oral presentation entitled "High doses ... the MS-SPI trial" will be given by Professor Ayman ... the 2nd Congress of the European Academy of Neurology (EAN) ... "MS and related disorders 3" will take place on Sunday, ...
Breaking Medicine Technology:
(Date:5/26/2016)... , ... May 26, 2016 , ... ... clinical outcomes, hosted members and suppliers for its inaugural Member Conference at the ... their mission of elevating the operational health of America’s healthcare providers. , The ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, through ... a partner for the Tamika Catchings Legacy Tour that will commemorate the ... in hardwood basketball surfaces in all forms and levels of the game, Connor Sports ...
(Date:5/26/2016)... ... ... The Woodlands at John Knox Village , Florida’s first Life Plan ... and healing, celebrated its grand opening, today. The Woodlands at John Knox Village is ... Staff. , “This is an incredibly fulfilling time for John Knox Village as we ...
(Date:5/26/2016)... ... ... There are nearly 14.5 million people living with and beyond cancer in the ... 2016, communities around the world will gather to recognize these cancer survivors as part ... is an annual worldwide Celebration of Life that is held on the first Sunday ...
(Date:5/26/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... global clinical supply services, today announced two key appointments and the opening of ... strategic growth plans in the Asia Pacific region. , Howard Kim has joined ...
Breaking Medicine News(10 mins):